In recent years, biotherapeutics have accounted for more than half of all approved drugs, with a significant number of them being monoclonal antibodies. These biotherapeutics undergo post-translational modifications and are known for their large and complex nature.
One valuable tool for the development of these therapeutic proteins is a cell line such as XtenCHO™ Race, which has the capability to produce such proteins effectively. ProteoGenix regularly utilizes this cell line to manufacture recombinant proteins for its clients and has now made it available in their product catalog due to the high demand from customers.
The XtenCHO™ Race Cells, derived from the CHO-K1 cell line of Chinese Hamster Ovarian cells, have been specifically engineered to support prolonged transient gene expression. Through genetic modifications, these cells exhibit improved plasmid-driven expression and enhanced plasmid maintenance. Notably, XtenCHO™ Race Cells can sustain transfected plasmids for up to 14 days without the need for additional feeding, enabling prolonged protein production.
These cells are well-suited for high-density suspension culture and are supported by the XtenCHO™ Expression Medium, designed to promote high viability and robust growth in these cells. With a doubling time of around 23 hours, XtenCHO™ Race Cells are not only efficient but also resilient and easy to cultivate, with a short recovery time of approximately 2 days after thawing.
In conclusion, XtenCHO™ Race Cells offer a reliable solution for achieving high levels of protein expression and are a valuable asset in the field of therapeutic development.
There are no reviews yet.